Hemophagocytic Lymphohistiocytosis (HLH)

Hemophagocytic Lymphohistiocytosis (HLH) is a life-threatening syndrome of uncontrolled immune activation where macrophages and histiocytes go haywire — engulfing blood cells and releasing massive amounts of cytokines. USMLE Step 1 tests this through clinical vignettes featuring a sick child with persistent high fever, pancytopenia, and a shockingly elevated ferritin, often with a viral trigger like EBV. The most common wrong turn is assuming HLH is a histiocytic malignancy — it isn't. The core defect is that NK cells and cytotoxic T-lymphocytes cannot kill their targets (perforin/granule pathway failure), so macrophages that should be shut down keep accumulating and driving cytokine storm. The primary vs. secondary distinction matters: primary HLH is genetic, while secondary (macrophage activation syndrome or MAS) is triggered by infection, malignancy, or rheumatologic disease.

The exam loves to test whether you understand what's mechanistically happening — impaired NK cell and cytotoxic T-lymphocyte killing leads to macrophage accumulation and cytokine storm, not unchecked tumor growth. Students who confuse HLH with histiocytic malignancies will chase the wrong diagnosis. The diagnostic criteria are fair game: fever, splenomegaly, cytopenias (≥2 lines), hypertriglyceridemia, hypofibrinogenemia, elevated ferritin (often >10,000 ng/mL), elevated soluble CD25, and hemophagocytosis on biopsy.

The tricky parts are the lab findings that seem counterintuitive. Fibrinogen goes DOWN despite active inflammation — because activated macrophages consume it, mimicking DIC. Ferritin goes astronomically UP — not from iron overload but from macrophage activation. USMLE Step 1 questions will often bury one of these lab abnormalities in a table and expect you to recognize the full pattern rather than fixate on one value.